S&P 500 5,235.18 +1.02%EUR/USD 1.0840 +0.21%GBP/USD 1.2710 +0.14%USD/JPY 149.50 −0.18%BRENT $82.40 −0.81%BTC $67,800 −0.21%GOLD $2,341 +0.55%NASDAQ 16,420.55 +0.74%S&P 500 5,235.18 +1.02%EUR/USD 1.0840 +0.21%GBP/USD 1.2710 +0.14%USD/JPY 149.50 −0.18%BRENT $82.40 −0.81%BTC $67,800 −0.21%GOLD $2,341 +0.55%NASDAQ 16,420.55 +0.74%
A daily business newspaper · Founded in 2026

Money Talk

Finance and markets: business, quotes, gold, energy and releases.

Keros Shares Rise 11% After $5 Million Buyback Approval

Keros Therapeutics shares climbed 11% to $11.12 on Tuesday after the company’s board approved a share repurchase program of up to $5 million. The gain followed a $20 million development milestone payment from Takeda Pharmaceuticals under a licensing agreement.

Keros Shares Rise 11% After $5 Million Buyback Approval

The clinical-stage biopharmaceutical company said the payment relates to elritercept, a drug now being tested in a clinical trial. Keros recently completed the first dosing of a patient in the trial.

Despite Tuesday’s rise, the stock remains down 45% this year.

Share article
TelegramXFacebook

When reusing this material a link to Money Talk is required.

Comments (0)

Leave a comment

No comments yet. Be the first!